Nomura Holdings Inc. Acquires 259,900 Shares of Allergan plc (NYSE:AGN)

Nomura Holdings Inc. increased its holdings in shares of Allergan plc (NYSE:AGN) by 528.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 309,062 shares of the company’s stock after acquiring an additional 259,900 shares during the period. Nomura Holdings Inc. owned about 0.09% of Allergan worth $51,810,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Clearbridge Investments LLC lifted its stake in shares of Allergan by 8.6% during the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock worth $1,342,141,000 after acquiring an additional 726,688 shares during the last quarter. Longview Partners Guernsey LTD lifted its stake in shares of Allergan by 10.7% during the 2nd quarter. Longview Partners Guernsey LTD now owns 6,986,566 shares of the company’s stock worth $1,169,761,000 after acquiring an additional 676,771 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Allergan by 6.5% during the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after acquiring an additional 410,746 shares during the last quarter. FMR LLC lifted its stake in shares of Allergan by 42.0% during the 1st quarter. FMR LLC now owns 6,042,005 shares of the company’s stock worth $884,611,000 after acquiring an additional 1,788,265 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Allergan by 1.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 3,001,582 shares of the company’s stock worth $439,462,000 after purchasing an additional 28,271 shares during the period. 80.45% of the stock is owned by hedge funds and other institutional investors.

NYSE:AGN traded up $0.92 during mid-day trading on Friday, reaching $166.65. The stock had a trading volume of 2,159,523 shares, compared to its average volume of 3,013,323. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.91 and a current ratio of 1.03. The firm has a market capitalization of $54.36 billion, a price-to-earnings ratio of 9.99, a PEG ratio of 2.16 and a beta of 1.61. Allergan plc has a twelve month low of $114.27 and a twelve month high of $197.00. The business has a 50 day simple moving average of $161.19 and a 200 day simple moving average of $149.43.

Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.34 by $0.04. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The company had revenue of $4.09 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period last year, the firm earned $4.42 EPS. The company’s revenue for the quarter was down .8% on a year-over-year basis. As a group, sell-side analysts expect that Allergan plc will post 16.68 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th were given a dividend of $0.74 per share. The ex-dividend date of this dividend was Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.78%. Allergan’s payout ratio is 17.74%.

Several research analysts have commented on AGN shares. Goldman Sachs Group started coverage on Allergan in a report on Tuesday, May 28th. They set a “neutral” rating and a $154.00 price objective on the stock. JPMorgan Chase & Co. set a $200.00 price objective on Allergan and gave the company a “buy” rating in a report on Wednesday, June 19th. Sanford C. Bernstein cut Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target on the stock. in a research note on Tuesday, July 16th. Leerink Swann cut Allergan from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $217.00 to $188.00 in a research note on Thursday, July 18th. Finally, Guggenheim cut Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have assigned a buy rating to the stock. Allergan has an average rating of “Hold” and a consensus target price of $178.75.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Further Reading: Equal Weight Rating

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.